Biotech Values

[dewophile]

zgen

Is the prospect of positive "ipi" results adversely affecting ZGEN or is there some other reason for this sharp drop in share price?

i don't think many people put much value on il-21 so i find it hard to believe upcoming data for competing compounds is really the cause of this drop - that said the timing near ASCO can't be ignored. the only way il-21 affects valuation imo is if zgen puts too much money into the program - i know the 2b is done with NCI canada and is relatively modest in size so i don't think it's money poorly spent, but perhaps others do

more likely the drop has to do with the significantly relaxed regulatory climate surrounding combination studies for HCV. this shortens the time frame for all oral cocktails to reach approval, assuming this is feasible. BMY is the first to come out with data from their trial at AASLD - it could hurt zgen if the non-inf arm does well, although the converse is also true and zgen could get a bump if the inf arm does better. of course bmy won't have svr data until next year, and relapses may very well be the reason why soc proves necessary so it won't exactly be game over for lamda even if the BMY non-inf data (evr, etc.) are strong